Chief Technical Operations sold 200,000 shares (89.3% reduction) of NUVB at $7.14; stock up 68.4% in 30 days, company unprofitable.
Hanley David C., Chief Technical Operations at Nuvation Bio, executed a substantial sale of 200,000 shares on 2025-11-19 at $7.14, reducing his holdings from 224,000 shares to 24,000 shares (an 89.3% reduction). This occurs against a backdrop of significant recent price appreciation: the stock has gained 68.4% over the past 30 days and 141.0% over 90 days, now trading at $6.99, just 2.2% below its 52-week high of $7.15. Despite the strong recent momentum, Nuvation Bio remains unprofitable with a net loss of $55,792,000.00 on revenue of $13,120,000.00 in its latest quarter, indicating fundamental challenges persist regardless of near-term share price strength. The magnitude of this insider stake reduction—nearly 9-of-10 shares sold by the CTO—combined with the stock's proximity to 52-week highs while the company sustains significant operating losses, presents a material signal for investor scrutiny of near-term catalysts and management confidence at elevated valuations.